



an Open Access Journal by MDPI

## The Role of Chaperone-Mediated Autophagy in Tissue Homeostasis and Disease Pathogenesis

Guest Editors:

**Dr. Rut Valdor**

University of Murcia-Biomedical  
Research Institute IMIB-Arrixaca,  
Murcia, Spain

**Dr. Marta Martinez-Vicente**

Neurodegenerative Diseases  
Research Group, Vall d'Hebron  
Research Institute-CIBERNED,  
Barcelona, Spain

Deadline for manuscript  
submissions:

**closed (31 August 2023)**

### Message from the Guest Editors

Dear Colleagues,

Chaperone-mediated autophagy (CMA) is a selective proteolytic pathway in the lysosomes. Proteins are recognized one-by-one through the detection of a KFERQ motif or, at least, KFERQ-like motif by a heat shock cognate protein 70 (Hsc70), a molecular chaperone. CMA substrates are recognized and delivered to a lysosomal CMA receptor, lysosome-associated membrane protein 2A (LAMP2A), the only limit component of this pathway, and transported to the lysosomal lumen with the help of another resident chaperone HSp90. Since approximately 75% of proteins are reported to have canonical, phosphorylation-generated, or acetylation-generated KFERQ motifs, CMA maintains intracellular protein homeostasis and regulates specific functions in the cells in different tissues. CMA also regulates physiologic functions in different organs and, then, is implicated to disease pathogenesis related to aging, cancer, and the central nervous and immune systems. This Special Issue focuses on the recent advances on the role of CMA in tissue homeostasis and the disease pathogenesis.

Dr. Rut Valdor

Dr. Marta Martinez-Vicente

*Guest Editors*



[mdpi.com/si/117842](https://mdpi.com/si/117842)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI